Gain Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GANX research report →
Range $5 – $5
Price Chart
About the company
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments.
- CEO
- Gene Mack
- IPO
- 2021
- Employees
- 21
- HQ
- Bethesda, MD, US
Get TickerSpark's AI analysis on GANX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $71.23M
- P/E
- -3.34
- Fwd P/E
- 5.22
- PEG
- -0.12
- P/S
- 0.00
- P/B
- 6.34
- EV/EBITDA
- -3.08
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -161.58%
- ROIC
- -157.82%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-18,710,702
- Net Income
- $-20,161,099+1.2%
- EPS
- $-0.61+31.5%
- OCF Growth
- +2.2%
- FCF Growth
- +2.3%
- 52W High
- $4.34
- 52W Low
- $1.53
- 50D MA
- $1.83
- 200D MA
- $2.00
- Beta
- 0.19
- RSI (14)
- 41
- Avg Volume
- 498.67K
No earnings-call transcripts are available for GANX yet.
- Free Float
- 97.6%
- Shares Outstanding
- 42.65M
- Float Shares
- 41.65M
of shares held by institutions
46 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Marshall Wace, Llp | 1.92M | ▲ 153.76K |
| Potomac Capital Management, Inc. | 946.40K | ▼ 62.20K |
| Gsa Capital Partners Llp | 632.13K | ▲ 319.66K |
| Jones Financial Companies Lllp | 608.59K | ▼ 23.02K |
| Vanguard Group Inc | 569.90K | ▲ 35.55K |
| Cambridge Investment Research Advisors, Inc. | 568.64K | 0 |
| Dme Capital Management, LP | 566.13K | 0 |
| Vanguard Capital Management LLC | 480.27K | ▲ 80.38K |
| Geode Capital Management, LLC | 453.50K | ▲ 6.16K |
| Blackrock, Inc. | 274.96K | ▲ 49.91K |
| Vanguard Fiduciary Trust Co | 231.53K | ▲ 1.55K |
| Ubs Group AG | 215.01K | ▼ 5.48K |
Held by 10 ETFs
Biggest fund positions in GANX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 15, 26 | GOLDSTEIN DOV A MD | other | 25,000 |
| Jul 15, 26 | Nicaise Claude | other | 25,000 |
| Jul 15, 26 | Islam Khalid | other | 25,000 |
| Jul 15, 26 | Melincoff Gwen A | other | 25,000 |
| Jul 15, 26 | Riley Jeffrey Scott | other | 25,000 |
| Jul 15, 26 | HASLER HANS PETER | other | 25,000 |
| Mar 24, 26 | Mack Gene | other | 200,000 |
| Mar 24, 26 | Fuggetta Gianluca | other | 50,000 |
| Jun 24, 25 | Islam Khalid | other | 15,000 |
| Jun 24, 25 | Nicaise Claude | other | 15,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GANX coverage
Recent articles, reports, and earnings notes.
No research on GANX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GANX report →Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
globenewswire.com · Oct 1
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson's Disease and Movement Disorders
globenewswire.com · Sep 29
Gain Therapeutics (NASDAQ:GANX) versus Spyre Therapeutics (NASDAQ:SYRE) Head to Head Comparison
defenseworld.net · Sep 28
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
globenewswire.com · Sep 17
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Aug 25
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
globenewswire.com · Jul 16
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease
globenewswire.com · Jun 29
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
globenewswire.com · Jun 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.